Roche Receives FDA Approval for Evrysdi® Tablet for Spinal Muscular Atrophy

 Roche  announced  that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam...

February 13, 2025 | Thursday | News
Pfizer Receives FDA Approval for ADCETRIS® Combination Therapy in Relapsed/Refractory Large B-Cell Lymphoma

 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for AD...

February 13, 2025 | Thursday | News
SpringWorks Therapeutics Secures FDA Approval for GOMEKLI™ to Treat Neurofibromatosis Type 1 with Plexiform Neurofibromas

SpringWorks Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced  that the U.S. Food ...

February 12, 2025 | Wednesday | News
Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® with Both IV and SC Formulations

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...

February 12, 2025 | Wednesday | News
Q32 Bio Restructures to Focus on Bempikibart's Development for Alopecia Areata, Discontinues ADX-097 Trial

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced a corporate restr...

February 11, 2025 | Tuesday | News
Convergent Therapeutics Announces Promising Clinical Trial Updates for CONV01-α at ASCO Genitourinary Cancers Symposium 2025

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...

February 11, 2025 | Tuesday | News
CSL’s HEMGENIX® Delivers Long-Term Bleed Protection for Hemophilia B with Four-Year Data from HOPE-B Study

 Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...

February 10, 2025 | Monday | News
Eli Lilly's Omvoh® Achieves Long-Term Clinical and Endoscopic Outcomes in Crohn's Disease Patients in VIVID-2 Study

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely acti...

February 10, 2025 | Monday | News
Merck Initiates Pivotal Phase 3 Trial of Zilovertamab Vedotin for Treatment of Diffuse Large B-Cell Lymphoma

Merck known as MSD outside of the United States and Canada, announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ziloverta...

February 10, 2025 | Monday | News
Genentech's Gazyva® Demonstrates Significant Improvement in Lupus Nephritis in Phase III REGENCY Trial

Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...

February 10, 2025 | Monday | News
Cencora Expands Sure Supply Program to Strengthen Drug Shortage Resilience

Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage...

February 07, 2025 | Friday | News
Alumis and ACELYRIN Announce Definitive Merger Agreement, Creating a Leading Immunology Biopharma with Late-Stage Pipeline Strength

Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...

February 07, 2025 | Friday | News
Intuitive BioTechnologies Expands Elemental Analysis Services in North America

Intuitive BioTechnologies LLC (IBT) is proud to announce they have added elemental analysis to their testing capabilities. IBT is now offering quantitati...

February 07, 2025 | Friday | News
BD Reports Strong Q1 2025 Results with $5.2B Revenue as CEO Tom Polen Announces Strategic Business Separation

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,  announced its financial results for the first quarter ...

February 06, 2025 | Thursday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close